Key result
In non-obese patients with polycystic ovary syndrome undergoing in vitro fertilization, higher HDL levels were associated with clinical pregnancy (OR 0.355), while hyperlipidemia increased total gonadotropin dosage requirements.
Why the study?
It was little known whether hyperlipidemia alone has adverse effects on IVF outcomes in patients with polycystic ovarian syndrome.
Does hyperlipidemia affect embryo quality and pregnancy outcomes in non-obese patients with PCOS undergoing IVF/ICSI?
Cohort (n=335)
No
Does hyperlipidemia affect embryo quality and pregnancy outcomes in non-obese patients with PCOS undergoing IVF/ICSI?
Odds Ratio: 0.355 (95% CI 0.135–0.938)
p-value: p=<0.05
Hyperlipidemia in non-obese PCOS patients undergoing IVF is associated with higher gonadotropin requirements and adverse effects on embryo quality and endometrial receptivity.
May warrant lipid assessment in non-obese PCOS IVF; leaves open whether management improves outcomes.
Introduction It is little known whether hyperlipidemia alone has adverse effects on the outcome of in vitro fertilization (IVF) in patients with polycystic ovarian syndrome (PCOS). Methods The PCOS patients with body mass index (BMI) < 30 kg/m2 were performed IVF or intracytoplasmic sperm injection treatment, including 208 fresh cycles and 127 frozen embryo transfer (FET) cycles. All the patients were divided into hyperlipidemia and control groups, and embryo quality and pregnancy outcomes between the two groups were compared. Results In the fresh cycles, total gonadotropin dosage in the control group was significantly lower than that in the hyperlipidemia group, and serum estradiol levels on trigger day were reversed (P < 0.05). The embryo fragment score was positively correlated with serum low-density lipoprotein level (r = 0.06, P < 0.05) and negatively with serum high-density lipoprotein (HDL) and lipoprotein A levels (r = -0.489 and -0.085, P < 0.01). Logistic regression analysis found that HDL was beneficial for clinical pregnancy (OR = 0.355, 95% CI: 0.135-0.938, P < 0.05). In the FET cycles, there were no differences in pulse index, systolic/diastolic ratio and serum estradiol and progesterone levels between the two groups, but resistance index in the hyperlipidemia group was significantly higher than that in the control group (P < 0.05). Conclusion Hyperlipidemia may increase the dosage of gonadotropin and have adverse effect on the embryo quality, endometrial receptivity, and clinical outcomes of lean PCOS patients. It is recommended that the non-obese patients with hyperlipidemia and PCOS perform lipid-lowering treatment before undergoing embryo transfer.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) conducted a cohort in Polycystic ovary syndrome (PCOS) (n=335). Hyperlipidemia vs. Normal lipid levels was evaluated on Clinical pregnancy (association with HDL in fresh cycles) (OR 0.355, 95% CI 0.135-0.938, p=<0.05). In non-obese patients with polycystic ovary syndrome undergoing in vitro fertilization, higher HDL levels were associated with clinical pregnancy (OR 0.355), while hyperlipidemia increased total gonadotropin dosage requirements.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: